http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8905309-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5cfa5e3c37268efbe83524e2f72716a
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4208
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
filingDate 1988-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62526e102e5157a070724e4c00b89db6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51f93b332250f9c908b3acd5053fc52f
publicationDate 1989-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-8905309-A1
titleOfInvention Method and means for selection of anti-idiotype antibodies and their use for the diagnosis, monitoring, treatment and/or prevention of cancer, autoimmune or infectious disease
abstract A selective anti-idiotype therapies of cancer, infectious disease or autoimmune disease, allergy or transplantation rejection. Prognostic idiotopes useful in disease diagnosis and/or monitoring are (i) identified and (ii) induced or suppressed by the therapeutic application of modulatory anti-idiotype antibodies, alone or in combination with other immunomodulating agents. Modulatory anti-idiotype antibodies and methods for making and using them in immunotherapy are claimed. Modulatory anti-idiotype antibodies may be made and used in active or passive immunotherapy according to the following method. First, idiotype bearing antibodies (Ab1s) are generated or acquired. Second, select at least one idiotype bearing Ab1 or T-cell which is reactive with a cancer, infectious agent or autoimmune disease target antigen, allergen or transplant antigen for future screening. Next, make at least one anti-id (Ab2) against the Ab1 or T-cell receptor. At this point, the anti-ids (Ab2s) made are screened. Each of the anti-ids (Ab2s) may be screened either against the B or T-cell idiotopes of either the sera, blood or tissue of a statistically significant panel of patients or against the serum, blood or tissue of a single patient or animal. In either case, the purpose of the screening is to identify a correlation between idiotope level and either (i) disease presence or progression, or (ii) disease absence or regression. Finally, that anti-id (Ab2) or combination of anti-ids (Ab2s) which induces either (1) suppression of idiotopes which normally fall with disease regression; (2) stimulation of idiotopes which normally rise with disease regression; (3) stimulation of idiotopes which normally fall with disease progression; or (4) suppression of idiotopes which normally rise with disease progression are administered.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0362755-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5869045-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5223426-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5980896-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6020145-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5766947-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0657471-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0362755-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5491088-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5792456-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6048526-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5980892-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9100295-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5728821-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9111456-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6171799-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5976533-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9111465-A1
priorityDate 1987-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4661586-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0133540-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18598300
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412774
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226442987
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399689
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399690
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24187255
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395454
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396360
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID84003
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2140
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7886
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID187
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396889

Total number of triples: 54.